Biphosphonates in advanced prostate and renal cell cancer - Current status and potential applications

Urologia Internationalis

Volumn 76, Issue 2, 2006, Pages 97-105

  Hoesl, C E ^a   Altwein, J E ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b KRANKENHAUS BARMHERZIGE BRÜDER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; CYTOKINE; ESTROGEN; ETIDRONIC ACID; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; IBANDRONIC ACID; LEUPRORELIN; MITOXANTRONE; NERIDRONIC ACID; PAMIDRONIC ACID; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; VITAMIN D; ZOLEDRONIC ACID;

ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; BONE DENSITY; BONE METASTASIS; BONE REMODELING; BONE TURNOVER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DIGITAL RECTAL EXAMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ECHOGRAPHY; FATIGUE; FEVER; HORMONAL THERAPY; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LITERATURE; MEDLINE; MYALGIA; NONHUMAN; ORCHIECTOMY; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PILOT STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PUBLICATION; QUALITY OF LIFE; RANDOMIZATION; REVIEW; SPINAL CORD COMPRESSION; STATISTICAL SIGNIFICANCE; VERTEBRA FRACTURE;

BONE NEOPLASMS; DISEASE PROGRESSION; HUMANS; KIDNEY NEOPLASMS; MALE; PHOSPHONIC ACIDS; PROSTATIC NEOPLASMS;

EID: 33745043053     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090869     Document Type: Review

References (73)

1. Daniell HW: Osteoporosis after orchiectomy for prostate cancer. J Urol 1997;157:439-444.
2. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT: Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000;163:181-186.
3. Kiratli BJ, Srinivas S, Perkash I, Terris MK: Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001;57:127-132.
4. Carlin BI, Andriole GL: The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000;88(suppl 12):2989-2994.
5. Zekri J, Ahmed N, Coleman RE, Hancock BW: The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 2001;19:379-382.
6. Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, Kanis JA, Kyle RA, Mundy GR, Paterson AH, Rubens RD: Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 1998;16:3890-3899.
7. Clezardin P, Fournier P, Boissier S, Peyruchaud O: In vitro and in vivo antitumor effects of bisphosphonates. Curr Med Chem 2003;10:173-180.
8. Green JR: Antitumor effects of bisphosphonates. Cancer 2003;97(suppl 3):840-847.
9. Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS: Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 2001;91:2238-2245.
10. Higano CS: Management of bone loss in men with prostate cancer. J Urol 2003;170:S59-S63.
11. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C: Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999;161:1219-1222.
12. Wei JT, Gross M, Jaffe CA, Gravlin K, Lahaie M, Faerber GJ, Cooney KA: Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 1999;54:607-611.
13. Diamond T, Campbell J, Bryant C, Lynch W: The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate cancer. Cancer 1998;83:1561-1566.
14. Eriksson S, Eriksson A, Stege R, Carlstrom K: Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 1995;57:97-99.
15. Lopez AM, Pena MA, Hernandez R, Val F, Martin B, Riancho JA: Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int 2005;16:707-711.
16. Coleman RE: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-176.
17. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, Moinuddin M: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988;61:195-202.
18. Lipton A, Zheng M, Seaman J: Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003;98:962-969.
19. Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G: Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res 2004;10:6397S-6403S.
20. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M, Zoledronic Acid Prostate Cancer Study Group: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-882.
21. Saad F: Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer 2002;1:145-152.
22. Oleksik AM, Ewing S, Shen W, van Schoor NM, Lips P: Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures. Osteoporos Int 2005;16:861-870.
23. Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, Schulman KA: The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16:579-584.
24. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI: Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002;168:1005-1007.
25. Oefelein MG, Ricchiuti VS, Conrad PW, Goldman H, Bodner D, Resnick MI, Seftel A: Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era. Urology 2002;60:120-124.
26. Tanvetyanon T: Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer 2005;103:237-241.
27. Moyad MA: Complementary therapies for reducing the risk of osteoporosis in patients receiving luteinizing hormone-releasing hormone treatment/ orchiectomy for prostate cancer: a review and assessment of the need for more research. Urology 2002;59(suppl 1):34-40.
28. Carlstrom K, Stege R, Henriksson P, Grande M, Gunnarsson PO, Pousette A: Possible bone-preserving capacity of high-dose intramuscular depot estrogen as compared to orchidectomy in the treatment of patients with prostatic carcinoma. Prostate 1997;31:193-197.
29. Stepan JJ, Lachman M, Zverina J, Pacovsky V, Baylink DJ: Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 1989;69:523-527.
30. Suzuki Y, Oishi Y, Yamazaki H: How to avoid bone loss in patients with prostatic carcinoma receiving long-term LHRH analogue. J Urol 2000;163:159.
31. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008-2012.
32. Lipton A: Toward new horizons: the future of bisphosphonate therapy. Oncologist 2004;9 (suppl 4):38-47.
33. Magno C, Anastasi G, Morabito N, Gaudio A, Maisano D, Franchina F, Gali A, Frisina N, Melloni D: Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate. Eur Urol 2005;47:575-580.
34. Diamond TH, Winters J, Smith A, De Souza P, Kersley JH, Lynch WJ, Bryant C: The anti-osteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double-blind, randomized, placebo-controlled crossover study. Cancer 2001;92:1444-1450.
35. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948-955.
36. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR: Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004;100:892-899.
37. Caroll PR, Altwein J, Brawley O, Cockett M, Cooperberg M, Hirao Y, Lobel B, McLeod D, Neal D, van Poppel H, Richard F, Scher H, Wood C: Management of disseminated prostate cancer; in Denis L, Bartsch G, Khoury S (eds): Prostate Cancer. 3rd International Consultation on Prostate Cancer, Paris. Paris, Health Publications, 2003, pp 249-284.
38. Lipton A: Bisphosphonates and breast carcinoma: present and future. Cancer 2000; 88(suppl 12):3033-3037.
39. Terpos E, Rahemtulla A: Bisphosphonate treatment for multiple myeloma. Drugs Today (Barc) 2004;40:29-40.
40. Adami S, Mian M: Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Recent Results Cancer Res 1989;116:67-72.
41. Elomaa I, Kylmala T, Tammela T, Viitanen J, Ottelin J, Ruutu M, Jauhiainen K, Ala-Opas M, Roos L, Seppanen J, et al: Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostatic cancer. Int Urol Nephrol 1992;24:159-166.
42. Kylmala T, Taube T, Tammela TL, Risteli L, Risteli J, Elomaa I: Concomitant intravenous and oral clodronate in the relief of bone pain - a double-blind placebo-controlled study in patients with prostate cancer. Br J Cancer 1997;76:939-942.
43. Heidenreich A, Hofmann R, Engelmann UH: The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 2001;165:136-140.
44. Strang P, Nilsson S, Brandstedt S, Sehlin J, Borghede G, Varenhorst E, Bandman U, Borck L, Englund G, Selin L: The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anticancer Res 1997;17:4717-4721.
45. Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, Chi K, Ding K, Elliott C, Parulekar W: Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003;21:3335-3342.
46. Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson AC, Thompson PM, Moffat LE, Naylor SL, Parmar MK: MRC PR05 Collaborators: A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003;95:1300-1311.
47. Smith JA Jr: Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J Urol 1989;141:85-87.
48. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO: Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003;21:4277-4284.
49. Heidenreich A, Elert A, Hofmann R: Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 2002;5:231-235.
50. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B, Zoledronic Acid Prostate Cancer Study Group: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-1468.
51. Kise H, Kobayashi K, Arima K, Yanagawa M, Tochigi H, Kawamura J, Hioki T, Sugiura Y: Effect of pamidronate and interferon-a on bone and lung metastases and hypercalcemia in a patient with renal cell carcinoma. Hinyokika Kiyo 1996;42:879-881.
52. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ, Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial. J Clin Oncol 2003;21:3150-3157.
53. Lindsay R: Bone loss after cardiac transplantation. N Engl J Med 2004;350:751-754.
54. Clarke NW, McClure J, George NJ: Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991;68:74-80.
55. Clarke NW, McClure J, George NJ: Osteoblast function and osteomalacia in metastatic prostate cancer. Eur Urol 1993;24:286-290.
56. Shimazaki J, Higa T, Akimoto S, Masai M, Isaka S: Clinical course of bone metastasis from prostatic cancer following endocrine therapy: examination with bone x-ray. Adv Exp Med Biol 1992;324:269-275.
57. Rodan GA, Fleisch HA: Bisphosphonates: mechanisms of action. J Clin Invest 1996;97:2692-2696.
58. Fisher JE, Rodan GA, Reszka AA: In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 2000;141:4793-4796.
59. Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, Hofbauer LC: Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002;291:680-686.
60. Green JR, Clezardin P: Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol 2002;25(suppl 1):S3-S9.
61. Montague R, Hart CA, George NJ, Ramani VA, Brown MD, Clarke NW: Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of zoledronic acid in prostate cancer. Eur Urol 2004;46:389-401.
62. Lee MV, Fong EM, Singer FR, Guenette RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001;61:2602-2608.
63. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA: Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88:2095-2105.
64. Teronen O, Heikkila P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, Teronen A, Maisi P, Sorsa T: MMP inhibition and downregulation by bisphosphonates. Ann NY Acad Sci 1999;878:453-465.
65. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J: Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002;116:278-290.
66. Senaratne SG, Mansi JL, Colston KW: The bisphosphonate zoledronic acid impairs Ras membrane localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 2002;86:1479-1486.
67. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-1061.
68. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, Salerno A, Denaro V, Tonini G: Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002;8:1080-1084.
69. Pecherstorfer M, Jilch R, Sauty A, Horn E, Keck AV, Zimmer-Roth I, Thiebaud D: Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations. J Bone Miner Res 2000;15:147-154.
70. Sansoni P, Passeri G, Fagnoni F, Mohagheghpour N, Snelli G, Brianti V, Engleman EG: Inhibition of antigen-presenting cell function by alendronate in vitro. J Bone Miner Res 1995;10:1719-1725.
71. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M: Stimulation of gd T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000;96:384-392.
72. Derenne S, Amiot M, Barille S, Collette M, Robillard N, Berthaud P, Harousseau JL, Bataille R: Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 1999;14:2048-2056.
73. Barille S, Akhoundi C, Collette M, Mellerin MP, Rapp MJ, Harousseau JL, Bataille R, Amiot M: Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood 1997;90:1649-1655.